Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
|Videos|August 3, 2022
Factors linked to increased likelihood of germline mutations in renal cell carcinoma
Author(s)Urology Times staff
“We saw that with each additional enrichment feature the odds of finding a germline mutation would double,” says Alexis Rompré-Brodeur, MD.
Advertisement
Alexis Rompré-Brodeur, MD, a urologic oncologist at McGill University discusses results of the study, “Germline testing in renal cell carcinoma: can enrichment features help predict germline alterations?” which he presented at the 2022 AUA Annual Meeting (
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Urology Times
1
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
2
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
3
FDA updates in urology: September 2026
4
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
5